Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)

NCT01729455 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01729455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01729455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
February 21, 2013
Completion date
February 28, 2025
Enrollment
3,138 (actual)
Sites
179

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus